Fraunhofer Institute for Cell Therapy and Immunology IZI

Optimising self-assembling molecular structures for use in diagnostics applications

Press release | June 29, 2018

more info

Non-human papillomaviruses as gene shuttle

Press release | June 19, 2018

more info

Manufacturing immunotherapeutics for the treatment of brain tumors – preliminary study results published

more info

We transfer biomedical research into the clinic.

The Fraunhofer Institute for Cell Therapy and Immunology IZI investigates and develops solutions to specific problems at the interfaces of medicine, life sciences and engineering.

One of the institute's main tasks is to conduct contract research for companies, hospitals, diagnostic laboratories and research institutes operating in the field of biotechnology, pharmaceuticals and medical engineering.

The Fraunhofer IZI develops, optimizes and validates methods, materials and products for the business units Cell and Gene Therapy, Drugs, Diagnostics and Biosystems Technology.

Its areas of competence lie in cell biology, immunology, drug biochemistry, biomarker, bioanalytics and bioproduction as well as process development and automation.

In these areas, research specifically focusses on the indications oncology, neuropathology, autoimmune and inflammatory diseases as well as infectious diseases and regenerative medicine.

The institute works in close cooperation with hospital institutions and performs quality tests besides carrying out the GMP-compliant manufacture of clinical test samples. Furthermore, it helps partners obtain manufacturing licenses and permits.

Business units

Jobs / career

Press

Publications

News

Press information / 29.6.2018

Optimising self-assembling molecular structures for use in diagnostics applications

Researchers from the Fraunhofer Institute for Cell Therapy and Immunology IZI, Harvard University and the University of Cambridge probing the mysteries of how DNA molecules can self-assemble into complex structures have found ways of tuning the assembly process to make it more efficient and significantly faster.

 

Press information / 19.6.2018

Non-human papillomaviruses as gene shuttle

Nucleic acids such as DNA and RNA are being drawn upon more and more in modern medicine, with  gene sequences, for instance, being applied in gene therapies and DNA vaccines. The latter of these offer multiple advantages compared with traditional vaccination methods as they are quick to manufacture, easy to adapt and are highly stable. Moreover, the coded antigens are produced by the body itself, meaning they are correctly modified and/or folded. Immunization using DNA vaccines activates both the cellular and the humoral immune defense, i.e. the production of antibodies by the B-lymphocytes, thus helping to provide effective protection against pathogens.

 

 

 

Press information / 8.6.2018

Manufacturing immunotherapeutics for the treatment of brain tumors – preliminary study results published

Between 2011 and 2017, the Fraunhofer Institute for Cell Therapy and Immunology assisted American biotech company Northwest Biotherapeutics, Inc. in the conduct of a phase three clinical trial investigating the efficacy of the new DCVax®-L cell therapy in the treatment of glioblastomas. Fraunhofer IZI was responsible for preparing the investigational medicinal products for the European part of the trial. On May 29, 2018, the company published initial clinical findings in the Journal of Translational Medicine.

 

Press information / 17.5.2018

Fighting pathogens with sugar molecules

Sugar can have many negative effects on the body. Overconsumption can give rise to obesity, high blood pressure and even diabetes. But there is more to sugar than meets the eye. For their next joint project, scientists from the Fraunhofer Institute for Cell Therapy and Immunology IZI and the Max Planck Institute of Colloids and Interfaces (MPIKG) have set their sights on polysaccharides. The two institutes will join forces to investigate how the arrangement of sugar molecules on DNA structures can be utilized to develop new antimicrobial agents. Planned to span a four-year period from May 2018, the “Glyco3Display” research project is being funded as part of the cooperation program between Fraunhofer and Max Planck.

Contact

Fraunhofer IZI

 

Perlickstraße 1
04103 Leipzig
Germany

Phone +49 341 35536-1000
Fax +49 341 35536-8-1000
E-mail info@izi.fraunhofer.de

 

 

Social Media